Section Arrow
AMLX.NASDAQ
- Amylyx Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/15 16:16 EDT
After Hours
Last
 13.55
-- (--)
Bid
12
Ask
14.16
High 13.55 
Low 13.03 
Volume 14.17K 
Regular Hours (Closed)
Last
 13.265
-0.615 (-4.43%)
Day High 
13.9 
Prev. Close
13.88 
1-M High
18.605 
Volume 
989.12K 
Bid
12
Ask
14.16
Day Low
13.17 
Open
13.54 
1-M Low
13.87 
Market Cap 
1.54B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 15.27 
20-SMA 16.14 
50-SMA 15.37 
52-W High 18.605 
52-W Low 4.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.48/-1.28
Enterprise Value
1.55B
Balance Sheet
Book Value Per Share
2.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
87.37M
Operating Revenue Per Share
1.73
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health25.05+0.81+3.34%-- 
After Hours 24.88 -0.17 -0.68%
CGCCanopy Growth Corp1.04-0.03-2.80%-- 
After Hours 1.03 -- --
VTRSViatris16.48-0.78-4.52%-- 
After Hours 16.42 -- --
HLNHaleon plc8.96+0.05+0.56%18.04PE
After Hours 8.96 0 0.00%
ZTSZOETIS74.22-1.26-1.67%12.17PE
After Hours 74.22 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.